Galmed Pharmaceuticals Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GLMD Nasdaq 2836 galmedpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galmed Pharmaceuticals Ltd.

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - Dec 8th, 2025 6:30 am
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - Dec 4th, 2025 6:30 am
Galmed Issues CEO Letter to Shareholders - Dec 1st, 2025 6:30 am
Galmed Pharmaceuticals: Q3 Earnings Snapshot - Nov 26th, 2025 6:56 am
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 26th, 2025 6:30 am
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - Nov 18th, 2025 6:30 am
BC-Most Active Stocks - Nov 17th, 2025 8:30 am
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - Nov 17th, 2025 6:30 am
Galmed Pharmaceuticals: Q2 Earnings Snapshot - Aug 28th, 2025 6:08 am
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 28th, 2025 6:00 am
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value - Aug 25th, 2025 5:30 am
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - May 27th, 2025 6:00 am
Galmed Pharmaceuticals: Q1 Earnings Snapshot - May 22nd, 2025 6:04 am
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - May 22nd, 2025 6:00 am
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - May 13th, 2025 6:00 am
Biotech Alert: Searches spiking for these stocks today - May 10th, 2025 9:55 am
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - May 6th, 2025 5:30 am
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - Apr 28th, 2025 6:00 am
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - Apr 17th, 2025 6:30 am
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Apr 15th, 2025 6:30 am